New hope for rare ovarian tumors: targeted drugs under study
NCT ID NCT04931342
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing several targeted drugs in people with rare types of ovarian cancer that have come back or not gone away. The drugs are chosen based on specific biomarkers in each patient's tumor. The goal is to see if these treatments can shrink or control the cancer. About 176 participants will receive one of four drugs: ipatasertib, cobimetinib, trastuzumab emtansine, or atezolizumab.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab
What this could lead to
If successful, this could provide effective treatment options for people with rare ovarian cancers that have returned or not responded to standard therapy.
What could go wrong
This is an early-phase study with a small number of participants. The drugs may not work for all tumor types, and side effects could limit their use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O. U. Consorziale Policlinico di Bari
Bari, Apulia, 70124, Italy
-
Adana Baskent University Medical Faculty; Oncology
Adana, 01220, Turkey (Türkiye)
-
Asan Medical Center
Seoul, 05505, South Korea
-
Baskent Universitesi Ankara Hastanesi; Tıbbi Onkoloji Bölümü
Ankara, 06490, Turkey (Türkiye)
-
CHU Besançon - Hôpital Jean Minjoz
Besançon, 25030, France
-
Cabrini Hospital
Malvern, Victoria, 3144, Australia
-
Centre Eugène Marquis
Rennes, 35042, France
-
Centre Francois Baclesse
Caen, 14076, France
-
Centre Leon Berard
Lyon, 69373, France
-
Groupe Hospitalier Diaconesses
Paris, 75020, France
-
Gustave Roussy
Villejuif, 94800, France
-
Gynekologicko-porodnicka klinika
Prague, 120 00, Czechia
-
Hospital Clinico Universitario Virgen de la Victoria
Málaga, 29010, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hôpitaux Universitaires de Genève
Geneva, 1205, Switzerland
-
ICO - Site René Gauducheau
Saint-Herblain, 44805, France
-
IRCCS S. Raffaele
Milan, Lombardy, 20132, Italy
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institutio Catalan De Oncologia
Barcelona, 08908, Spain
-
Istituto Tumori Napoli
Naples, Campania, 80131, Italy
-
Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie
Essen, 45136, Germany
-
Koc University Medical Faculty; Department of Gynecology & Obstetrics
Istanbul, 34010, Turkey (Türkiye)
-
LLC Medscan
Moskva, Moscow Oblast, 119421, Russia
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
McGill University Health Centre - Glen Site
Montreal, Quebec, H4A 3J1, Canada
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Policlinico Universitario Agostino Gemelli
Rome, Lazio, 00168, Italy
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 1Z5, Canada
-
Samsung Medical Center
Seoul, (0)6351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Texas Oncology - Gulf Coast
The Woodlands, Texas, 77380, United States
-
UCSF Helen Diller Family CCC
San Francisco, California, 94158, United States
-
University College London Hospitals NHS Foundation Trust - University College Hospital
London, NW1 2PG, United Kingdom
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Washington - Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
Universitätsklinikum Mannheim
Mannheim, 68167, Germany
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
-
Washington University School of Medicine
St Louis, Missouri, 63108, United States
-
Western General Hospital
Edinburgh, EH4 2XU, United Kingdom